17,726 Shares in Halozyme Therapeutics, Inc. $HALO Acquired by Element Squared LLC

Element Squared LLC purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 17,726 shares of the biopharmaceutical company’s stock, valued at approximately $1,193,000.

Other institutional investors have also recently bought and sold shares of the company. Empowered Funds LLC acquired a new position in Halozyme Therapeutics in the first quarter worth $755,000. Acadian Asset Management LLC acquired a new stake in shares of Halozyme Therapeutics in the first quarter valued at $195,000. State Board of Administration of Florida Retirement System raised its holdings in shares of Halozyme Therapeutics by 26.8% in the second quarter. State Board of Administration of Florida Retirement System now owns 48,160 shares of the biopharmaceutical company’s stock valued at $2,505,000 after buying an additional 10,180 shares during the last quarter. Hsbc Holdings PLC raised its holdings in shares of Halozyme Therapeutics by 117.1% in the second quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company’s stock valued at $522,000 after buying an additional 5,448 shares during the last quarter. Finally, Norges Bank acquired a new position in Halozyme Therapeutics during the 2nd quarter worth about $45,027,000. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock opened at $64.49 on Friday. The company has a market cap of $7.64 billion, a PE ratio of 25.90, a PEG ratio of 0.26 and a beta of 1.03. The company has a current ratio of 4.66, a quick ratio of 3.66 and a debt-to-equity ratio of 43.89. Halozyme Therapeutics, Inc. has a 1 year low of $47.50 and a 1 year high of $82.22. The company’s 50-day moving average is $69.94 and its two-hundred day moving average is $69.38.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of $1.92 by ($2.16). Halozyme Therapeutics had a return on equity of 136.12% and a net margin of 22.69%.The business had revenue of $451.77 million for the quarter, compared to the consensus estimate of $446.13 million. During the same period last year, the firm earned $1.26 earnings per share. The company’s quarterly revenue was up 51.6% on a year-over-year basis. Equities analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Analysts Set New Price Targets

HALO has been the topic of a number of research analyst reports. Wall Street Zen cut shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Saturday, February 21st. TD Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, February 18th. Benchmark increased their price target on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, January 29th. Finally, Wells Fargo & Company boosted their price objective on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 19th. Six equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Halozyme Therapeutics currently has a consensus rating of “Hold” and an average target price of $78.56.

Insider Buying and Selling at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $64.24, for a total transaction of $1,284,800.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $49,322,187.20. The trade was a 2.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 2,000 shares of the stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $70.25, for a total value of $140,500.00. Following the completion of the transaction, the director directly owned 40,123 shares in the company, valued at $2,818,640.75. The trade was a 4.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 110,857 shares of company stock worth $7,785,087. Insiders own 2.40% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.